小分子c-Met激酶抑制剂的研究进展  

Advances in Research on c-Met Kinase Inhibitors

作　　者：胡亚宁[1] 胡诗合 袁浩亮[1] 庄津[1] 陈亚东[2] 陆涛[1] 

机构地区：[1]中国药科大学有机化学教研室,江苏南京211198 [2]中国药科大学无机化学教研室,江苏南京211198

出　　处：《药学进展》2015年第3期170-178,共9页Progress in Pharmaceutical Sciences

基　　金：国家自然科学基金(No.81473078)

摘　　要：受体酪氨酸激酶c-Met即肝细胞生长因子HGF受体。HGF/c-Met信号通路在肿瘤形成、生长和转移过程中被频繁激活,因此,c-Met已成为抗癌药物研究中一个重要靶标。重点介绍近年来基于c-Met通路的抗癌药物研究进展。c-Met kinase is the receptor for hepatocyte growth factor（HGF）. HGF/c-Met is frequently activated during the development, growth and metastasis of tumor. Therefore, c-Met becomes an important target in anti-cancer therapy. The advances in research on c-Met inhibitors recent years have been reviewed in this paper.

关 键 词：c-Met激酶 HGF/c-Met通路 c-Met抑制剂 肿瘤 

分 类 号：R979.1[医药卫生—药品]